Business
Prothena Announces that Novo Nordisk Will Advance Coramitug (Formerly PRX004) into Phase 3 Development for ATTR Amyloidosis with Cardiomyopathy
DUBLIN, August 06, 2025--Prothena announced that Novo Nordisk communicated that they expect to advance coramitug into a Phase 3 program for ATTR-CM in 2025.
About this update from Prothena Corporation Plc
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":3612,"height":1160,"url":"https://media.zenfs.com/en/business-wire.com/5fa4627a22d146263d4bfab481a13ac1"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/M7VbrhBPrIWMKHOgKtuLIA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTMwODtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/5fa4627a22d146263d4bfab481a13ac1","width":960,"height":308},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/aeK33gLicTzvYh6ng7GG4w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD03NzA7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/5fa4627a22d146263d4bfab481a13ac1","width":1200,"height":385}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Coramitug is a potential first-in-class amyloid depleter antibody for the treatment of ATTR amyloidosis with cardiomyopathy1-3","length":126,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Novo Nordisk successfully completed a Phase 2 trial with coramitug and is expected to initiate a Phase 3 program in 2025","length":120,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Prothena to earn a clinical milestone payment when prespecified enrollment criteria are met in a Phase 3 clinical trial by Novo Nordisk","length":135,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":381,"olType":false},{"type":"text","content":"DUBLIN, August 06, 2025--(BUSINESS WIRE)--Prothena Corporation plc (NASDAQ:PRTA), announced that Novo Nordisk communicated during their second quarter 2025 earnings call on August 6, 2025 that they expect to advance coramitug, a potential first-in-class amyloid depleter antibody, into a Phase 3 program for ATTR amyloidosis with cardiomyopathy (ATTR-CM) in 2025. Coramitug was initially developed by Prothena and was acquired by Novo Nordisk in July 2021.","length":456,"tagName":"p"},{"type":"text","content":""We are excited by Novo Nordisk’s decision to advance coramitug into Phase 3 development. There remains a significant unmet need in patients with ATTR amyloidosis with cardiomyopathy, who are at high risk for early mortality and significant morbidity due to amyloid deposition in vital organs," said Gene Kinney, Ph.D., President and Chief Executive Officer, Prothena.","length":378,"tagName":"p"...